Information on this blog is being shared only for the purpose of creating legal awareness in public at large, especially in the field of Intellectual Property Right. As there may be possibility of error, omission or mistake in legal interpretation on the contents of this blog, it should not be treated as substitute for legal advise.
Monday, March 10, 2025
Pawan Kumar Goel Vs. Dr. Dhan Singh
Bayer Corporation Vs. Union of India
BOLAR PROVISION:Section 107 A of Patent Act 1970:Section 107A permits the sale and export of patented drugs for regulatory approval in other countries and for research purpose only.
Introduction:
The case of Bayer Corporation vs. Union of India & Ors., decided by the Delhi High Court on April 22, 2019, concerns the interpretation of Section 107A of the Patents Act, 1970, commonly known as the "Bolar provision."
The central issue in this case was whether the sale or export of a patented drug for the purpose of regulatory approval in another country constitutes patent infringement.
Bayer Corporation, a multinational pharmaceutical company, filed legal proceedings against Natco Pharma and Alembic Pharmaceuticals, challenging their export of patented drugs under Section 107A. The case is significant for its impact on the pharmaceutical industry, particularly concerning the balance between patent rights and the promotion of generic medicines.
Factual Background:
Bayer Corporation held a patent for Sorafenib Tosylate, a drug used to treat kidney and liver cancer, under Patent No. 215758. In 2011, Natco Pharma applied for a compulsory license under Section 84 of the Patents Act, which was granted in 2012 by the Patent Controller. The license allowed Natco to manufacture and sell the drug in India at an affordable price. However, Bayer filed a writ petition when it discovered that Natco was also exporting Sorafenib Tosylate outside India, arguing that this was beyond the scope of the compulsory license.
Simultaneously, Alembic Pharmaceuticals was manufacturing and exporting Rivaroxaban, another patented drug, for regulatory purposes. Bayer filed a suit against Alembic, alleging that its export of Rivaroxaban infringed Bayer’s patent rights. Alembic contended that the exports were covered under Section 107A, which allows the sale of patented products solely for uses reasonably related to the development and submission of information required under any law.
Procedural Background:
Bayer initially filed a suit against Natco in 2011, seeking an injunction against the sale and export of Sorafenib Tosylate. The Patent Controller granted a compulsory license to Natco in 2012. Bayer then approached the Delhi High Court, seeking to prevent Natco from exporting the drug.
In parallel, Bayer filed a suit against Alembic in 2016, seeking an injunction against the export of Rivaroxaban. During the proceedings, Alembic argued that its exports were permissible under Section 107A.
The learned Single Judge ruled in favor of Natco and Alembic, holding that Section 107A permitted the sale and export of patented drugs for regulatory purposes. Bayer appealed the decision, leading to the present judgment by the Division Bench of the Delhi High Court.
Issues Involved in the Case:
The primary issue in this case was whether Section 107A of the Patents Act permits the export of patented drugs for the purpose of obtaining regulatory approvals in other countries?
Whether the word "sale" in Section 107A includes export or is limited to sales within India?
Whether the acts of Natco and Alembic constituted infringement under Section 48 of the Patents Act.
Whether the purpose of Section 107A was to facilitate only the Indian market or to allow global generic competition.
Whether the burden of proof lay on the patent holder (Bayer) or the generic manufacturers (Natco and Alembic) to prove the intended use of the patented product.
Submissions of the Parties:
Bayer argued that Section 107A is an exception to the patentee's rights under Section 48 and should be interpreted narrowly. Bayer contended that the provision does not explicitly mention "export," and therefore, sale under this section should be restricted to India. Bayer further relied on foreign precedents, including the U.S. Bolar exemption and German and Polish case law, to argue that the sale of a patented drug for regulatory purposes should be limited to the domestic market. Bayer emphasized that allowing exports under Section 107A would contravene the TRIPS Agreement and international patent norms.
Natco and Alembic countered that Section 107A allows the sale of patented products for the purpose of developing and submitting regulatory information in other countries. They argued that the plain language of the provision does not restrict sale to India. They also pointed out that regulatory authorities in many countries require local clinical trials, which necessitate the export of the drug. They cited WTO rulings and global practices to support their interpretation.
Discussion on Judgments and Citations:
The court examined the legislative intent behind Section 107A and compared it with similar provisions in other jurisdictions. The court relied on the WTO Dispute Settlement Panel's ruling in the Canada-Patent Protection of Pharmaceutical Products case (WTO/DS114/R), which upheld the Bolar exemption. The court also referred to the U.S. Supreme Court’s decision in Merck v. Integra Lifesciences (545 U.S. 193), which interpreted the American Bolar exemption broadly.
Additionally, the court considered the decision in Intermedics Inc. v. Ventritex (775 F. Supp. 1269), which allowed the export of patented products for regulatory approval. The court rejected Bayer’s reliance on German and Polish case law, holding that Indian law provides a broader exemption than those jurisdictions.
Reasoning and Analysis of the Judge:
The court held that the plain meaning of Section 107A does not restrict "sale" to India and that the term includes exports.
It observed that the provision was intended to facilitate the development of generic medicines globally and that restricting sales to India would defeat this purpose. The court noted that requiring generic manufacturers to conduct separate trials in each country would be impractical and contrary to international trade practices.
The court also rejected Bayer’s argument that the burden of proof should be on the generic manufacturers. It held that placing the burden on the patentee to prove wrongful use was consistent with international norms and would prevent unnecessary litigation.
The court further reasoned that allowing exports under Section 107A was consistent with India’s obligations under the TRIPS Agreement, as it did not unreasonably prejudice the patent holder’s rights. The court emphasized that regulatory approvals are necessary for timely market entry and that a restrictive interpretation of Section 107A would hinder access to affordable medicines.
Final Decision:
The Delhi High Court upheld the Single Judge’s ruling and dismissed Bayer’s appeal.
The court held that Section 107A permits the sale and export of patented drugs for regulatory approval in other countries and for research purpose only.
It ruled that Bayer had failed to establish that Natco and Alembic’s actions amounted to infringement.
The court also directed that Bayer’s patents could not be used to block exports of drugs intended solely for regulatory purposes.
Law Settled in This Case
The judgment clarified that Section 107A of the Patents Act includes the right to export patented drugs for regulatory approval. The decision reinforced that patent rights are subject to reasonable exceptions aimed at promoting public health and access to medicines. The ruling also established that the burden of proof lies on the patentee to prove infringement rather than on the generic manufacturer to justify its actions.
Case Details:
Bajaj Electricals Limited Vs Metals & Allied Products
The plaintiff's sales grew significantly, with revenues climbing to ₹73.94 crores by 1986. Bajaj's products were heavily advertised, gaining substantial market recognition.
The defendants, Metals & Allied Products, began manufacturing kitchen utensils in 1976-77 and allegedly used the "Bajaj" mark since then. In February 1977, they applied to register the mark for stainless steel utensils under Class 21, but this application was deemed abandoned. A subsequent application for registration was filed in 1984. Despite this, the defendants continued using the mark and claimed their surname "Bajaj" entitled them to do so.
During this hearing, the defendants claimed their use of the mark since 1976, producing invoices, affidavits, and certificates from traders. The Single Judge eventually ruled against granting a full injunction but ordered the defendants to modify their branding to prominently display the manufacturer’s name along with the “Bajaj” mark.
Issues Involved in the Case:
- Whether the defendants' use of the mark "Bajaj" constituted passing off.
- Whether the defendants had established prior use of the mark dating back to 1977.
- Whether the defendants’ use of the mark, even if honest, was likely to cause deception or confusion.
- Whether the defendants' claim of using their family name in trade was legitimate.
- They had established significant goodwill and reputation for their products under the "Bajaj" mark.
- The defendants had deliberately adopted the mark to take advantage of this reputation.
- The defendants' use of the mark, combined with misleading statements in their brochure, was evidence of bad faith.
- The invoices produced by the defendants were dubious and possibly fabricated.
The defendants contended that:
- They had been using the mark “Bajaj” since 1976 and had made applications for its registration.
- The mark was derived from the surname of the partners, which entitled them to use it in trade.
- Their products differed from those of the plaintiffs, reducing the likelihood of confusion.
- They had obtained certifications from traders and had been using stickers bearing the “Bajaj” name since 1979.
The court also referred to Joseph Rodgers & Sons Ltd. v. W.N. Rodgers & Co. [(1924) 41 R.P.C. 277], which emphasized that even honest use of one’s name could be restrained if it resulted in consumer deception.
The court examined Kerly’s Law of Trade Marks and Trade Names, which highlights that once bad faith or intent to deceive is established, the user cannot claim a defense based on their right to use a family name.
The court found that the defendants’ brochure, which claimed “Bajaj quality is well accepted internationally,” was misleading since the defendants had no presence in international markets. This was considered evidence of deliberate misrepresentation.
- The plaintiffs had established substantial goodwill and reputation in the "Bajaj" mark.
- The defendants’ claims of long-standing use were unsubstantiated; the invoices presented were suspicious and lacked credibility.
- The fact that the defendants had issued a misleading brochure in 1987 further evidenced bad faith.
- The defense of using one’s surname in trade could not justify conduct that created confusion among consumers.
- The defendants' attempt to differentiate their mark through changes in font and capital letters was insufficient to prevent consumer deception.
B.L. And Co. And Others Vs. Pfizer Products Inc.
Introduction: The case of B.L. And Co. And Others vs. Pfizer Products Inc. revolves around the alleged passing off of the drug 'VIAGRA' by the defendants through their product 'PENEGRA'. The dispute primarily concerns the deceptive similarity in trade names, trade dress, and product appearance. Pfizer, the plaintiff, sought an injunction restraining the defendants from manufacturing and marketing 'PENEGRA', claiming that it infringed upon its global reputation and goodwill associated with 'VIAGRA'. The case was heard before the Delhi High Court, which passed an ex parte injunction against the defendants, leading to an appeal.
Factual Background:Pfizer, a global pharmaceutical company, introduced 'VIAGRA' (sildenafil citrate) in 1998 for the treatment of male erectile dysfunction. The trade mark 'VIAGRA' was registered in various jurisdictions and had pending registration in India. Pfizer contended that the brand had achieved international recognition and had been extensively advertised worldwide, including in India.
The defendants, B.L. & Co. and Others, introduced a similar product under the name 'PENEGRA' in January 2001. The plaintiff discovered the existence of 'PENEGRA' through an internet search and media reports, which referred to it as 'Indian VIAGRA'. Pfizer alleged that the defendants intentionally adopted a deceptively similar trade name and trade dress, including the distinctive blue diamond-shaped tablet. Further, the defendants had allegedly copied elements from Pfizer's website onto their own, thereby misleading consumers and capitalizing on Pfizer's goodwill.
Procedural Background:Pfizer filed a suit for injunction and damages for passing off before the Delhi High Court. On June 1, 2001, the Single Judge granted an ex parte injunction under Order XXXIX Rules 1 and 2 CPC, restraining the defendants from manufacturing, marketing, or selling 'PENEGRA' or any product deceptively similar to 'VIAGRA'. The appellants challenged this order before a Division Bench of the Delhi High Court on multiple grounds, including the alleged failure of the Single Judge to consider crucial legal principles governing the grant of ex parte injunctions.
Issues Involved in the Case:
Whether the trade mark 'PENEGRA' was deceptively similar to 'VIAGRA'?
Whether Pfizer, despite not selling 'VIAGRA' in India, could claim passing off based on trans-border reputation?
Whether the Single Judge’s grant of an ex parte injunction was justified?
Whether there was undue delay by Pfizer in filing the suit, and if so, whether it impacted its right to relief?
Whether the balance of convenience favored the defendants, considering their established market presence?
Submissions of the Parties Plaintiff (Pfizer):
'VIAGRA' had acquired immense international goodwill and reputation, extending to India despite not being directly marketed.
The defendants deliberately chose the name 'PENEGRA' to deceive consumers and exploit the reputation of 'VIAGRA'.
The distinctive blue diamond-shaped tablet had been copied, further contributing to the likelihood of confusion.
The copying of website content demonstrated mala fide intent.
The principles of passing off allowed Pfizer to protect its brand even in jurisdictions where it had not commenced commercial operations.
Defendants (B.L. & Co. and Others):
'PENEGRA' was developed independently after extensive research and clinical trials.
The product had been in the market for over five months before the suit was filed, indicating delay on Pfizer's part.
The pronunciation and spelling of 'PENEGRA' were distinct from 'VIAGRA', and the packaging and branding were different.
The balance of convenience lay in favor of the defendants, as they had invested significantly in product development and marketing.
Pfizer’s product was not marketed in India, and hence, there was no possibility of deception or passing off.
Discussion on Judgments and Citations
Wander Ltd. v. Antox India (P) Ltd., 1990 (Supp) SCC 727: The Supreme Court held that interlocutory injunctions should balance the need to protect the plaintiff's rights against the defendant’s legitimate business operations. The High Court referred to this case in assessing the necessity of the injunction.
N.R. Dongre v. Whirlpool Corporation, 1996 PTC (16) 583 (SC): The Supreme Court upheld passing off claims based on trans-border reputation, which Pfizer relied upon.
Daimler Benz Aktiegesellscaft v. Hybo Hindustan, 1994 PTC 287: The Delhi High Court protected the reputation of international brands, even in the absence of direct business operations in India.
The Financial Times Ltd. v. Evening Standard Co. Ltd. (1991) FSR 7: A case concerning delay in seeking an injunction, which was used by the defendants to argue against Pfizer's claim.
Reasoning and Analysis of the Judge The Division Bench found that the Single Judge failed to consider critical factors before granting an ex parte injunction. These included:
The defendants had been manufacturing and marketing 'PENEGRA' for over five months before Pfizer took action.
Pfizer had knowledge of the defendants’ activities but delayed seeking legal recourse, indicating acquiescence.
The lack of availability of 'VIAGRA' in India weakened Pfizer’s claim of passing off.
The Single Judge did not record reasons justifying the urgency required for an ex parte injunction under Order XXXIX Rule 3 CPC.
The Bench noted that an interlocutory injunction should be granted only after hearing both parties unless the object of the injunction would be defeated by delay. In the absence of specific reasons recorded by the Single Judge, the ex parte order was deemed unsustainable.
Final Decision The Division Bench set aside the ex parte injunction granted by the Single Judge, allowing the defendants to continue manufacturing and marketing 'PENEGRA'. However, the defendants undertook to change the tablet’s color and refrain from using website content copied from Pfizer’s site. They were also directed to maintain records of production and sales.
Law Settled in This Case
Ex parte injunctions must be granted only when justified by urgency, with reasons explicitly recorded under Order XXXIX Rule 3 CPC.
Delay in seeking relief is a crucial factor against granting an interlocutory injunction in passing off cases.
Trans-border reputation can be a valid basis for a passing off claim, but its application depends on the facts of each case.
Balance of convenience must be weighed carefully, especially when the defendant has an established market presence.
Astrazeneca AB & Anr. Vs. Westcoast Pharmaceutical Works Ltd.
There is no statutory bar on instituting Patent infringement suit while post-grant opposition is pending
Introduction: Astrazeneca AB & Anr. filed a suit against Westcoast Pharmaceutical Works Ltd. alleging patent infringement. The plaintiffs contended that the defendant was manufacturing and selling a pharmaceutical product that infringed upon their patented invention. The defendant, in response, filed an application under Order VII Rule 11 of the Code of Civil Procedure (CPC), 1908, seeking the rejection of the suit based on grounds of want of pecuniary jurisdiction, want of territorial jurisdiction, and applicability of the Supreme Court's judgment in Aloys Wobben v. Yogesh Mehra.
Detailed Factual Background: The plaintiffs, Astrazeneca AB and its Indian subsidiary, claimed to hold a valid patent for the compound Osimertinib under patent number IN 297581. The patent was granted on June 11, 2018. The plaintiffs contended that the defendant was attempting to manufacture and distribute a product that infringed on their patent rights.
Post-grant oppositions were filed against the patent by Sunshine Organics Pvt. Ltd. on May 14, 2019, and by Natco Pharma Ltd. on June 10, 2019. The plaintiffs argued that despite these oppositions being pending before the Controller General of Patents, they retained the right to file an infringement suit. The defendant, in contrast, argued that the plaintiffs' rights were not crystallized until the resolution of post-grant opposition proceedings.
Detailed Procedural Background: The plaintiffs filed a commercial intellectual property rights (IPR) suit before the Delhi High Court, seeking an injunction to restrain the defendant from manufacturing or selling the allegedly infringing product. In response, the defendant filed an application under Order VII Rule 11 CPC, seeking rejection of the plaint based on:
Lack of pecuniary jurisdiction
Lack of territorial jurisdiction
Applicability of the Supreme Court's judgment in Aloys Wobben, which the defendant claimed precluded the filing of an infringement suit while post-grant opposition proceedings were pending.
Issues Involved in the Case:
Whether the suit was maintainable despite the pending post-grant opposition proceedings?
Whether the decision in Aloys Wobben precluded the plaintiffs from filing an infringement suit while the post-grant opposition was pending?
Detailed Submission of Parties Plaintiffs' Arguments:
The plaintiffs asserted that Section 11A(3) of the Patents Act allows an infringement suit to be filed once a patent is granted and does not mandate waiting for post-grant opposition proceedings to conclude.
They relied on precedents such as Novartis AG v. Natco Ltd. and CDE Asia Ltd. v. Terex India Pvt. Ltd., which held that the right to sue for infringement exists immediately upon the grant of a patent.
The plaintiffs argued that the judgment in Aloys Wobben was inapplicable to their case, as it dealt with the issue of whether a party could file both a revocation petition and a counterclaim in an infringement suit, not with the maintainability of an infringement suit pending post-grant opposition.
Defendant's Arguments:
The defendant relied on para 19 of the Aloys Wobben judgment, arguing that the plaintiffs’ patent rights had not crystallized while post-grant opposition proceedings were pending.
They claimed that as per the judgment in Toni & Guy Products Ltd. v. Shyam Sunder Nagpal, the suit should have been filed before a lower court due to lack of pecuniary jurisdiction.
They further argued that the court lacked territorial jurisdiction under Section 20 CPC, as the defendant’s principal place of business was outside Delhi.
Detailed Discussion on Judgments Cited and Their Context:
Aloys Wobben v. Yogesh Mehra (2014) 15 SCC 360: The Supreme Court held that once a party has filed a revocation petition, they cannot file a counterclaim in an infringement suit. The plaintiffs argued that this case was distinguishable as it did not discuss the maintainability of an infringement suit during post-grant opposition.
Novartis AG v. Natco Ltd.: The Delhi High Court held that a patentee could sue for infringement even while a post-grant opposition was pending.
CDE Asia Ltd. v. Terex India Pvt. Ltd.: The court reaffirmed that the pendency of a post-grant opposition does not preclude the filing of an infringement suit.
Toni & Guy Products Ltd. v. Shyam Sunder Nagpal: The court found that the valuation of damages in a quia timet action does not establish pecuniary jurisdiction unless actual damages are demonstrable.
Sergi Transformer Explosion Prevention Technologies Pvt. Ltd. v. CTR Manufacturing Industries Ltd.: The Bombay High Court initially held that a post-grant opposition impacted an infringement suit, but the Supreme Court overturned this decision, allowing the suit to proceed.
Detailed Reasoning and Analysis of the Judge: The Delhi High Court, presided over by Justice C. Hari Shankar, rejected the defendant’s application under Order VII Rule 11 CPC, reasoning as follows:
The court held that there is no statutory bar on instituting an infringement suit while post-grant opposition is pending. The only requirement under Section 11A(3) of the Patents Act is that a patent must be granted before an infringement suit can be filed.
The court distinguished the case from Aloys Wobben, noting that the Supreme Court’s observations in para 19 were obiter dicta and not binding precedents.
On pecuniary jurisdiction, the court found that the plaintiff had adequately pleaded damages exceeding the threshold for the Delhi High Court’s jurisdiction.
On territorial jurisdiction, the court held that the plaintiffs had a subordinate office in Delhi, and the infringing products were likely to be sold in Delhi, satisfying jurisdictional requirements.
Final Decision The Delhi High Court dismissed the defendant’s application under Order VII Rule 11 CPC, allowing the suit to proceed. The court reaffirmed that a patentee can initiate an infringement suit immediately upon the grant of a patent, irrespective of pending post-grant oppositions.
Law Settled in This Case:
The mere pendency of a post-grant opposition does not bar a patentee from filing an infringement suit.
The right to sue for infringement crystallizes upon the grant of a patent under Section 11A(3) of the Patents Act.
The Supreme Court’s observations in para 19 of Aloys Wobben are obiter dicta and do not constitute binding precedent.
Pecuniary jurisdiction is established if damages are claimed in excess of the court’s threshold, even in a quia timet suit.
Territorial jurisdiction exists where the infringing products are sold or likely to be sold, even if the defendant's principal place of business is elsewhere.
Karan Johar Vs India Pride Advisory Pvt. Ltd. & Ors.
Fact of the Case:
Karan Johar, a well-known filmmaker and television personality, filed a lawsuit against India Pride Advisory Pvt. Ltd. and others for using his name, "Karan Johar," in the title of the cinematographic film “Shaadi Ke Director Karan Aur Johar.” He alleged that the use of his name without consent violated his personality and publicity rights, causing commercial and reputational harm.
Procedural Background (in Brief):
- The plaintiff discovered the film's trailer on June 5, 2024, and issued a cease-and-desist notice on June 6, 2024.
- As the defendants did not respond, the plaintiff urgently filed a commercial IPR suit and an interim application seeking an injunction.
- The Bombay High Court granted an ad-interim injunction on June 13, 2024, preventing the release of the film.
- The defendants later sought to vacate the injunction but agreed to modify the film's publicity and some content.
Reasoning of the Court:
- Personality and Publicity Rights: The Court recognized that Karan Johar, being a highly reputed public figure, has an economic and legal right to control the use of his name.
- Commercial Exploitation: The Court found that the defendants’ use of "Karan Johar" in the film’s title and dialogues directly associated the film with the plaintiff, attempting to commercially exploit his goodwill.
- Irrelevance of Censor Board Certification: The Court ruled that a CBFC certification does not evaluate violations of personality or publicity rights, so it could not override Johar’s claim.
- Inadequacy of Defendants' Modifications: The Court found that merely adding "Aur" between "Karan" and "Johar" did not remove the association with the plaintiff.
Decision:
The Bombay High Court upheld Karan Johar’s claim and granted an injunction preventing the defendants from using his name in the title and promotional materials of the film. The Court ruled in favor of Johar, confirming that his personality and publicity rights had been infringed.
Case Details:
- Case Title: Karan Johar Vs India Pride Advisory Pvt. Ltd. & Ors.
- Date of Order: March 7, 2025
- Case Number: Comm IPR Suit (L) No. 17863 of 2024
- Name of Court: Bombay High Court
- Name of Hon’ble Judge: Justice R.I. Chagla
P. Pandian v. The Registrar of Trade Marks
Fact of the Case:
The petitioner, P. Pandian, sought renewal of the trademark WAHEED (TM No. 573302) in Class 24. The trademark was registered on 15.05.1992, and a registration certificate was issued on 12.09.2020 after a long procedural delay. However, upon checking the online registry, the petitioner found that the trademark was listed as expired on 15.05.2002. The petitioner was unable to file a renewal application online due to system inaccessibility and hence approached the High Court seeking a writ of mandamus to permit renewal.
Procedural Background in Brief
- Trademark application was filed on 15.05.1992.
- After an examination report and a hearing, the petitioner awaited advertisement before acceptance.
- The advertisement was published in the Trade Marks Journal on 03.02.2020.
- The registration certificate was issued on 12.09.2020.
- The trademark status on the online registry reflected an expiry date of 15.05.2002.
- The petitioner did not receive a notice of expiry under Rule 58(1) of the Trade Marks Rules, 2017.
- The petitioner was unable to file a renewal application due to online portal inaccessibility, leading to the filing of the writ petition.
Reasoning of the Court
- Failure to Provide Notice: The Trade Marks Rules require that a notice be issued to the trademark holder before the expiration of the registration. Since no such notice was issued, the petitioner was entitled to apply for renewal.
- Precedents Considered: The Court relied on the Bombay High Court's decision in Motwane Private Ltd. v. Registrar of Trade Marks and the Madras High Court’s own decision in Jaisuryas Retail Ventures Pvt. Ltd. v. The Registrar of Trade Marks, which held that failure to issue an expiry notice allows the proprietor to seek renewal.
- No Removal from Register: Since the trademark had not been officially removed from the register, the petitioner still had the right to apply for renewal.
Decision
The Madras High Court allowed the writ petition and directed the Registrar of Trade Marks to:
- Provide access to the online portal for the petitioner to file the renewal application.
- Alternatively, permit the petitioner to submit the renewal application and required documents in physical form.
- There was no order as to costs.
Case Details
- Case Title: P. Pandian v. The Registrar of Trade Marks
- Date of Order: 13.02.2025
- Case Number: W.P.(IPD) No.36 of 2024
- Court: High Court of Judicature at Madras
- Hon’ble Judge: Justice Senthilkumar Ramamoorthy
Tahoe Research Ltd. Vs. The Controller of Patents
Sunday, March 9, 2025
Havells India Limited Vs. Cab-Rio Industries
Fact of the Case:
Havells India Limited, the plaintiff, is a well-established company engaged in the business of electrical and power distribution equipment, including cables, wires, and other industrial and domestic circuit protection devices. The plaintiff has been using the brand name "REO" since 2012 and claims that it is a well-known trademark. The plaintiff obtained trademark registration for "REO" under classes 7, 9, and 11 and was granted copyright registration for its packaging. The plaintiff alleged that Cab-Rio Industries, the defendants, were manufacturing and selling electrical cables and wires under the name "CAB-RIO," which was deceptively similar to the plaintiff’s mark. The plaintiff contended that the defendants adopted the mark dishonestly to mislead consumers and pass off their products as those of the plaintiff. The plaintiff filed a suit seeking a permanent injunction against the defendants for trademark infringement and passing off.
The defendants argued that they had been using the mark "CAB-RIO" since 2017 and had a valid trademark registration for the same under Class 9. They contended that their mark was distinct and that the term "CAB" referred to cables, which was a descriptive term. The defendants further claimed that the plaintiff’s trademark registration was invalid as a third-party rectification petition was pending against it. The defendants also argued that the plaintiff’s brand "REO" was often used along with the "Havells" brand, and thus, there was no likelihood of confusion among consumers.
Procedural Background in Brief:
The plaintiff filed the suit for a permanent injunction against the defendants in the Delhi High Court, along with an application for an interim injunction under Order XXXIX Rules 1 and 2 of the Code of Civil Procedure, 1908. On November 11, 2024, the Court issued summons and appointed a Local Commissioner to inspect the defendants' premises. The Local Commissioner conducted an inspection on November 18, 2024, and prepared an inventory of the defendants’ products. After hearing both parties, the Court reserved judgment on January 27, 2025, and delivered its decision on February 17, 2025.
Reasoning of the Court:
The Court analyzed the plaintiff’s claim of prior use and found that the plaintiff had produced invoices showing use of the mark "REO" since 2012, while the defendants' earliest invoice under the mark "CAB-RIO" was from 2019. Based on this, the Court held that the plaintiff was the prior user of the mark. The Court compared the marks "REO" and "CAB-RIO" and observed that the dominant and prominent part of the defendants’ mark was "RIO," which was phonetically and structurally similar to "REO." The Court relied on the principles laid down in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd. (2001) and S. Syed Mohideen v. P. Sulochana Bai (2016) to determine deceptive similarity. The Court emphasized that consumers, particularly electricians, contractors, and builders, were of average intelligence and imperfect recollection, making them susceptible to confusion between the two marks.
The Court rejected the defendants' contention that "CAB-RIO" should be considered as a whole and found that the defendants’ use of the mark was not bona fide. It noted that the defendants had failed to provide any reasonable explanation for adopting the mark "RIO." The Court also found that the defendants' website and advertisements used "CAB" as an acronym for cables, reinforcing the likelihood of confusion. The Court concluded that the adoption of the mark "CAB-RIO" was intended to ride on the goodwill of the plaintiff’s mark "REO."
Decision:
The Court granted an interim injunction in favor of the plaintiff, restraining the defendants from using, selling, soliciting, exporting, advertising, or dealing in electrical cables and wires under the mark "CAB-RIO" or any other mark deceptively similar to "REO" until the final adjudication of the suit. The Court also directed the defendants to change their corporate name within one month.
Case Ttitle: Havells India Limited Vs. Cab-Rio Industries & Ors.Date of Order: February 17, 2025
Case Number: CS(COMM) 995/2024 & I.A. 44613/2024
Neutral Citation: Not provided in the document
Court: High Court of Delhi
Hon’ble Judge: Hon'ble Justice Shri Amit Bansal
Tapton Tea Company Vs. The Liptons Ltd.
Priya Enterprises vs. Prestige Housewares (India) Ltd.
Lakha Ram Sharma Vs. Balar Marketing Pvt. Ltd
Chunulal Seetaram vs. G.S. Muthiah and Brothers & Ors.
Alpha Foundation for Education and Research Vs. Akara Education Private Limited
Fact of the Case:
Alpha Foundation for Education and Research, a charitable educational trust established in 1993, had been using the trademarks "AKARA," "AKARA STAR KIDS," and its associated logo for its educational institutions since 2011. The plaintiff was the registered proprietor of these trademarks under Classes 41 and 16. Akara Education Private Limited applied for the registration of the trademark "AKARA" in Classes 9, 37, and 41. The appellant opposed these applications, claiming that the impugned trademark was identical to or deceptively similar to its own, leading to confusion among the public.
The opposition notices were filed by the appellant on various dates in 2017, challenging the respondent's trademark applications. However, the Assistant Registrar of Trade Marks rejected the opposition, treating it as abandoned on procedural grounds due to a delay in filing evidence. The appellant challenged this order, arguing that it was not given a fair opportunity to present its case.
Procedural Background in Brief:
The appellant filed opposition notices in 2017, objecting to the respondent's trademark applications. The Assistant Registrar of Trade Marks fixed different hearing dates for the cases. The appellant submitted its evidence under Rule 45(1) of the Trade Marks Rules but filed it after the stipulated two-month period. The Assistant Registrar rejected the evidence for being belated and held that the opposition was abandoned.
The appellant challenged these orders before the Intellectual Property Appellate Board (IPAB), but due to the dissolution of IPAB, the cases were transferred to the Madras High Court. The matter was heard by Justice N. Seshasayee, who examined whether the rejection of the opposition on procedural grounds was justified.
Reasoning of the Court:
The court observed that the Assistant Registrar failed to comply with Section 21(3) read with Rule 44(1) of the Trade Marks Rules, 2017 and Rule 49(1) of the Trade Marks Rules, 2022, which require the Registrar to serve a copy of the counter-statement on the opponent. The court found that there was no proof that the counter-statement was duly served on the appellant, which was a crucial procedural requirement before evidence could be demanded from the opponent.
The court further held that Rule 45(2) of the Trade Marks Rules, 2017, was procedural and directory in nature and could not override the substantive right of the opponent to contest the registration of a trademark. The Registrar's decision to reject the opposition merely on the ground of delay in submitting evidence was found to be arbitrary and inconsistent with the purpose of maintaining the purity of the trademark register.
The court reasoned that the Registrar could not insist on the submission of evidence unless the counter-statement had been properly served on the opponent. Since the Registrar failed to prove that the counter-statement was duly served, the rejection of the opposition as abandoned was unsustainable. The benefit of doubt had to be given to the opponent, as what was at stake was the statutory right to oppose the registration of a potentially conflicting trademark.
Decision:
The Madras High Court set aside the impugned orders of the Assistant Registrar of Trade Marks. It directed the Registrar to restore the opposition along with the appellant’s evidence and pass a fresh order on merits within four months. The appeals were allowed with no order as to costs.
Case Title: Alpha Foundation for Education and Research Vs. Akara Education Private Limited & Anr.
Date of Order: March 13, 2024
Case Number: (T)CMA(TM) No.82 of 2023 and other connected appeals
Neutral Citation: Not specified
Name of Court: Madras High Court
Name of Hon’ble Judge: Hon’ble Justice N. Seshasayee
Abdul Ghani Ahmad Vs. Registrar of Trade Marks
Blog Archive
-
►
2008
(3)
- ► 12/28 - 01/04 (3)
-
►
2009
(7)
- ► 03/08 - 03/15 (1)
- ► 03/22 - 03/29 (2)
- ► 09/13 - 09/20 (1)
- ► 12/20 - 12/27 (3)
-
►
2012
(31)
- ► 09/16 - 09/23 (31)
-
►
2013
(47)
- ► 05/12 - 05/19 (7)
- ► 08/04 - 08/11 (9)
- ► 08/11 - 08/18 (11)
- ► 08/18 - 08/25 (5)
- ► 08/25 - 09/01 (2)
- ► 09/01 - 09/08 (6)
- ► 09/08 - 09/15 (1)
- ► 10/06 - 10/13 (2)
- ► 12/22 - 12/29 (2)
- ► 12/29 - 01/05 (2)
-
►
2014
(1)
- ► 01/12 - 01/19 (1)
-
►
2015
(2)
- ► 03/01 - 03/08 (2)
-
►
2016
(27)
- ► 10/09 - 10/16 (23)
- ► 10/16 - 10/23 (1)
- ► 11/13 - 11/20 (2)
- ► 11/27 - 12/04 (1)
-
►
2017
(49)
- ► 04/23 - 04/30 (16)
- ► 04/30 - 05/07 (1)
- ► 05/07 - 05/14 (3)
- ► 05/14 - 05/21 (2)
- ► 05/21 - 05/28 (3)
- ► 05/28 - 06/04 (1)
- ► 06/11 - 06/18 (1)
- ► 06/25 - 07/02 (1)
- ► 07/30 - 08/06 (1)
- ► 08/06 - 08/13 (3)
- ► 08/13 - 08/20 (1)
- ► 08/20 - 08/27 (1)
- ► 09/03 - 09/10 (2)
- ► 09/24 - 10/01 (3)
- ► 10/29 - 11/05 (1)
- ► 11/12 - 11/19 (2)
- ► 11/26 - 12/03 (1)
- ► 12/10 - 12/17 (6)
-
►
2018
(76)
- ► 01/14 - 01/21 (2)
- ► 01/28 - 02/04 (3)
- ► 02/18 - 02/25 (1)
- ► 03/11 - 03/18 (2)
- ► 03/25 - 04/01 (1)
- ► 04/01 - 04/08 (4)
- ► 04/08 - 04/15 (2)
- ► 04/29 - 05/06 (2)
- ► 05/06 - 05/13 (3)
- ► 05/13 - 05/20 (33)
- ► 05/20 - 05/27 (4)
- ► 06/03 - 06/10 (1)
- ► 07/08 - 07/15 (1)
- ► 07/22 - 07/29 (1)
- ► 08/05 - 08/12 (4)
- ► 08/12 - 08/19 (1)
- ► 08/19 - 08/26 (1)
- ► 08/26 - 09/02 (2)
- ► 09/09 - 09/16 (1)
- ► 09/16 - 09/23 (1)
- ► 10/07 - 10/14 (1)
- ► 10/14 - 10/21 (1)
- ► 11/04 - 11/11 (1)
- ► 12/23 - 12/30 (3)
-
►
2019
(18)
- ► 01/20 - 01/27 (1)
- ► 01/27 - 02/03 (1)
- ► 02/03 - 02/10 (1)
- ► 02/10 - 02/17 (1)
- ► 03/03 - 03/10 (2)
- ► 03/31 - 04/07 (1)
- ► 04/07 - 04/14 (1)
- ► 04/14 - 04/21 (1)
- ► 06/02 - 06/09 (1)
- ► 06/09 - 06/16 (1)
- ► 06/30 - 07/07 (1)
- ► 08/04 - 08/11 (2)
- ► 09/01 - 09/08 (1)
- ► 09/08 - 09/15 (1)
- ► 09/22 - 09/29 (1)
- ► 12/22 - 12/29 (1)
-
►
2020
(6)
- ► 02/23 - 03/01 (2)
- ► 03/22 - 03/29 (1)
- ► 04/12 - 04/19 (1)
- ► 09/27 - 10/04 (1)
- ► 10/18 - 10/25 (1)
-
►
2022
(166)
- ► 06/12 - 06/19 (11)
- ► 06/19 - 06/26 (12)
- ► 06/26 - 07/03 (6)
- ► 07/03 - 07/10 (8)
- ► 07/10 - 07/17 (13)
- ► 07/17 - 07/24 (6)
- ► 07/24 - 07/31 (6)
- ► 07/31 - 08/07 (8)
- ► 08/07 - 08/14 (5)
- ► 08/14 - 08/21 (7)
- ► 08/21 - 08/28 (18)
- ► 08/28 - 09/04 (10)
- ► 09/04 - 09/11 (11)
- ► 09/11 - 09/18 (10)
- ► 09/18 - 09/25 (5)
- ► 09/25 - 10/02 (2)
- ► 10/02 - 10/09 (3)
- ► 10/09 - 10/16 (3)
- ► 10/16 - 10/23 (2)
- ► 10/23 - 10/30 (3)
- ► 10/30 - 11/06 (1)
- ► 11/06 - 11/13 (10)
- ► 11/13 - 11/20 (6)
-
►
2023
(190)
- ► 02/26 - 03/05 (1)
- ► 03/05 - 03/12 (3)
- ► 03/12 - 03/19 (1)
- ► 03/19 - 03/26 (2)
- ► 04/02 - 04/09 (3)
- ► 04/09 - 04/16 (1)
- ► 04/16 - 04/23 (1)
- ► 04/30 - 05/07 (1)
- ► 06/25 - 07/02 (2)
- ► 07/02 - 07/09 (5)
- ► 07/09 - 07/16 (2)
- ► 07/16 - 07/23 (13)
- ► 07/23 - 07/30 (9)
- ► 07/30 - 08/06 (4)
- ► 08/06 - 08/13 (12)
- ► 08/13 - 08/20 (1)
- ► 08/20 - 08/27 (12)
- ► 09/03 - 09/10 (9)
- ► 09/10 - 09/17 (7)
- ► 09/17 - 09/24 (10)
- ► 09/24 - 10/01 (7)
- ► 10/01 - 10/08 (8)
- ► 10/08 - 10/15 (6)
- ► 10/15 - 10/22 (9)
- ► 10/22 - 10/29 (4)
- ► 10/29 - 11/05 (6)
- ► 11/05 - 11/12 (6)
- ► 11/12 - 11/19 (5)
- ► 11/19 - 11/26 (3)
- ► 11/26 - 12/03 (4)
- ► 12/03 - 12/10 (8)
- ► 12/10 - 12/17 (5)
- ► 12/17 - 12/24 (10)
- ► 12/24 - 12/31 (5)
- ► 12/31 - 01/07 (5)
-
►
2024
(361)
- ► 01/07 - 01/14 (4)
- ► 01/14 - 01/21 (4)
- ► 01/21 - 01/28 (7)
- ► 01/28 - 02/04 (3)
- ► 02/04 - 02/11 (16)
- ► 02/11 - 02/18 (7)
- ► 02/18 - 02/25 (7)
- ► 02/25 - 03/03 (7)
- ► 03/03 - 03/10 (12)
- ► 03/10 - 03/17 (14)
- ► 03/17 - 03/24 (7)
- ► 03/24 - 03/31 (11)
- ► 03/31 - 04/07 (2)
- ► 04/07 - 04/14 (4)
- ► 05/12 - 05/19 (31)
- ► 05/19 - 05/26 (6)
- ► 05/26 - 06/02 (12)
- ► 06/02 - 06/09 (21)
- ► 06/09 - 06/16 (16)
- ► 06/16 - 06/23 (12)
- ► 06/23 - 06/30 (8)
- ► 06/30 - 07/07 (6)
- ► 07/07 - 07/14 (13)
- ► 07/14 - 07/21 (12)
- ► 07/21 - 07/28 (8)
- ► 07/28 - 08/04 (21)
- ► 08/04 - 08/11 (10)
- ► 08/11 - 08/18 (13)
- ► 08/18 - 08/25 (16)
- ► 08/25 - 09/01 (8)
- ► 09/01 - 09/08 (6)
- ► 09/08 - 09/15 (6)
- ► 09/15 - 09/22 (6)
- ► 09/22 - 09/29 (13)
- ► 09/29 - 10/06 (7)
- ► 10/06 - 10/13 (4)
- ► 12/29 - 01/05 (1)
-
►
2025
(1119)
- ► 01/05 - 01/12 (17)
- ► 01/12 - 01/19 (17)
- ► 01/19 - 01/26 (16)
- ► 01/26 - 02/02 (14)
- ► 02/02 - 02/09 (8)
- ► 02/09 - 02/16 (28)
- ► 02/16 - 02/23 (40)
- ► 02/23 - 03/02 (40)
- ► 03/02 - 03/09 (42)
- ► 03/09 - 03/16 (35)
- ► 03/16 - 03/23 (33)
- ► 03/23 - 03/30 (20)
- ► 03/30 - 04/06 (28)
- ► 04/06 - 04/13 (10)
- ► 04/13 - 04/20 (20)
- ► 04/20 - 04/27 (12)
- ► 04/27 - 05/04 (36)
- ► 05/04 - 05/11 (30)
- ► 05/11 - 05/18 (40)
- ► 05/18 - 05/25 (27)
- ► 05/25 - 06/01 (17)
- ► 06/01 - 06/08 (15)
- ► 06/08 - 06/15 (13)
- ► 06/15 - 06/22 (19)
- ► 06/22 - 06/29 (32)
- ► 06/29 - 07/06 (33)
- ► 07/06 - 07/13 (24)
- ► 07/13 - 07/20 (31)
- ► 07/20 - 07/27 (19)
- ► 07/27 - 08/03 (9)
- ► 08/03 - 08/10 (12)
- ► 08/10 - 08/17 (27)
- ► 08/17 - 08/24 (24)
- ► 08/24 - 08/31 (29)
- ► 08/31 - 09/07 (29)
- ► 09/07 - 09/14 (21)
- ► 09/14 - 09/21 (11)
- ► 09/21 - 09/28 (18)
- ► 09/28 - 10/05 (3)
- ► 10/05 - 10/12 (5)
- ► 10/12 - 10/19 (15)
- ► 10/19 - 10/26 (10)
- ► 10/26 - 11/02 (11)
- ► 11/02 - 11/09 (8)
- ► 11/09 - 11/16 (13)
- ► 11/16 - 11/23 (14)
- ► 11/23 - 11/30 (24)
- ► 11/30 - 12/07 (24)
- ► 12/07 - 12/14 (30)
- ► 12/14 - 12/21 (10)
- ► 12/21 - 12/28 (39)
- ► 12/28 - 01/04 (17)
-
▼
2026
(235)
- ► 01/04 - 01/11 (25)
- ► 01/11 - 01/18 (17)
- ► 01/18 - 01/25 (12)
- ► 01/25 - 02/01 (17)
- ► 02/01 - 02/08 (12)
- ► 02/08 - 02/15 (6)
- ► 02/15 - 02/22 (12)
- ► 02/22 - 03/01 (14)
- ► 03/01 - 03/08 (13)
- ► 03/15 - 03/22 (12)
- ► 03/22 - 03/29 (7)
- ► 03/29 - 04/05 (6)
- ► 04/12 - 04/19 (29)
- ► 04/19 - 04/26 (27)
- ► 04/26 - 05/03 (20)
- ▼ 05/03 - 05/10 (6)
Featured Post
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK REGISTRA...
-
Introduction In the dynamic realm of pharmaceutical innovation, where intellectual property rights safeguard groundbreaking discoveries, th...
-
A Party is not allowed to argue a case, what is not pleaded. Introduction: This case revolves around a fundamental principle of civil proce...
My Blog List
-
2 - हवाओं पर कोई सवाल हूँ मैं खुद ही एक मिसाल हूँ मैं? हाल,खयाल,कमाल,हाल,जंजाल === सुराग तेरी कोशिशें नाकाम मुझमें ढूँढ क्या लोगे तुम, अब तक तो मैं हीं ना र...3 days ago
-
IPL:Spice In, Nationality Out - I was sitting in my office. It was a hot afternoon. The fan was running slowly and making strange sounds like an old typewriter. Files were lying on my d...1 year ago
-
-
My other Blogging Links
- Ajay Amitabh Suman's Poem and Stories
- Facebook-My Judgments
- Katha Kavita
- Lawyers Club India Articles
- My Indian Kanoon Judgments
- Linkedin Articles
- Speaking Tree
- You Tube-Legal Discussion
- बेनाम कोहड़ा बाजारी -Facebook
- बेनाम कोहड़ा बाजारी -वर्ड प्रेस
- बेनाम कोहड़ा बाजारी-दैनिक जागरण
- बेनाम कोहड़ा बाजारी-नवभारत टाइम्स
- बेनाम कोहड़ा बाजारी-ब्लॉग स्पॉट
- बेनाम कोहड़ा बाजारी-स्पीकिंग ट्री